Pluri : Investor Presentation – Q3 2024

Nasdaq: PLUR

TASE: PLUR.TA

INVESTOR PRESENTATION

July 2024

FORWARD LOOKING STATEMENT

This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the "Company" or "Pluri"), to the extent such statements do not relate to historical or current facts. For example, the Company is using forward looking statements when it discusses its commercialization, development, and manufacturing activities, the potential of its technology to improve quality of life, change human course and make the world a better place, the potential benefits of Pluri's technology, the number of potential applications of Pluri's cell expansion technology, the potential applications of Pluri's and Ever After Foods' products, the statement that any mass cell production industry can benefit from Pluri's technology, its ability to seek and collaborate with strategic partners, its ability to continue and to expand its collaboration with Tnuva, its ability to solve medicine's most urgent unmet needs, the belief that cell therapy can lead to smart therapies which heal and regenerate the human body, the belief that cell therapy is an innovative treatment for ever-growing and aging population, the belief that the study results demonstrate PLX-PAD's ability to trigger muscle regeneration and maintain it over time, that the increase in muscle strength demonstrated in the PLX-PAD study is meaningful clinical evidence that PLX-PAD can be potentially beneficial for a variety of injuries, that PLX-R18 can stimulate the regeneration of damaged bone marrow following Hematopoietic Cell Transplantation, that Pluri will be able to scale up and scale out the Company's studies, that cell-based therapy will reshape the agricultural landscape and redefine the possibilities of sustainable crop production, the potential of Pluri's cell-based coffee to create new solutions and the ability of Pluri's cell-based technology platform to add value to many verticals and industries. Forward-looking statements are based on management's current expectations, estimates, projections, and assumptions about future events, and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions about the Company, which are difficult to predict, including projections of the Company's future financial results, its anticipated growth strategies, and anticipated trends in its business and in the market generally. Therefore, actual future results, performance and trends may differ materially from these forward-looking statements due to a variety of factors, including, without limitation: changes in technology and market requirements; the Company may encounter delays or obstacles in launching and/or successfully completing its proposed plans, including research and development; its products may not be approved by regulatory agencies, their technology may not be validated as they progress further and their methods may not be accepted; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real world settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. The factors listed above are not exclusive, and further information is contained in the Company's Annual Report on Form 10-K and other reports on file with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this presentation. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company. The information to be presented is not intended to replace the need to review the Company's formal filings with the U.S Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K and any subsequent filings, prior to making any investment in the Company's securities. In case of any inconsistencies between the information provided in this presentation and the Company's regulatory filings, the latter will prevail. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission.

2

AGING AND HEALTH

CLIMATE CHANGE

FOOD SECURITY

SUSTAINABILITY

SOLUTIONS FOR HUMANITY'S

GREATEST CHALLENGES

WE OFFER ROBUST CELL EXPANSION TECHNOLOGY PLATFORMS THAT CREATE NEW CELL-BASEDSOLUTIONS.

OUR TECHNOLOGY HAS THE POTENTIAL TO IMPROVE QUALITY OF LIFE AND MAKE OUR WORLD A BETTER PLACE.

3

PLURI AT A GLANCE

COMPANY

• Nasdaq (PLUR), TASE (PLUR.TA)
• Cash & deposits: ~$27 million (as of March 31,

2024)

• Based in Israel with global presence, including in the USA and Europe
• Rich IP portfolio with 140 patents granted globally
• In-house GMP manufacturing facility
• Two decades of experience in cell processing and mass scale technology development

INDUSTRIES

Regenerative medicine:	Cultivated meat
cell therapies	collaboration with Tnuva
	and other global food giants

Contract Development and	Cell-based coffee and
Manufacturing Organization	collaborations industry
	leaders

PARTNERS

4

OUR GREATEST ASSET

The Pluri technology platforms leverage the basic building blocks of life-cells-to create medicine, food and cell-based materials that can change the course of human history.

TECHNOLOGY ADVANTAGES

Patented, proprietary 3D cell expansion technology to produce high-qualitycells in mass quantities

Scalable, automated, efficient, reliable and fully controlled process

Cost-effective, consistent and validated process

Suitable for multiple cell sources: human, animal and plant

Robust in-house GMP (Good Manufacturing Practice) manufacturing facility

Proven batch-to-batch consistency

Manufacturing process approved by key regulators

5

PLURIMATRIX™

PluriMatrix™ is a breakthrough system for unprecedented industrial scale production of cell-basedproducts

PLURIMATRIX™ ADVANTAGES

Significantly increases industrial scale production of cell-based

products by using a packed-bedsystem

Flexible production to power a range of cell-basedproducts for

industries such as pharma, biologics, foodtech, agri-tech and beyond

Enables simultaneous expansion of various cell types within the same platform, giving each cell type its own growth space PluriMatrix' state-of-the-art modular cell production system enables a smaller infrastructure, significantly reducing cost and ecological

footprint

6

BUSINESS DEVELOPMENT STRATEGY

Development and	Partnerships that
manufacturing of	leverage Pluri's
innovative cell-based	technology to meet cell-
products using Pluri's	based manufacturing
3D cell expansion	needs for a variety of
technology	industries

7

PLURI'S CELL EXPANSION TECHNOLOGY PLATFORMS

The potential applications are almost endless.

Any industry that requires mass cell production can potentially benefit from Pluri's patented technology.

ONE

TECHNOLOGY,

MANY

SOLUTIONS

8

OUR MISSION

To leverage our advanced cell expansion platforms and position as a global leader in cell technology to develop, manufacture and market highly effective cell-based products and solutions that enhance global wellbeing and promote sustainability

And many other industries…

9